CFA
LOGC

Carroll Financial Associates’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Carroll Financial Associates’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$1K Hold
428
– – ﹤0.01% 1593
2021
Q3 		$1K Hold
428
– – ﹤0.01% 1751
2021
Q2 		$1K Hold
428
– – ﹤0.01% 1671
2021
Q1 		$3K Buy
+428
New +$3.52K ﹤0.01% 1475

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return

Carroll Financial Associates's LOGC Position: Q4 2021 in Review

Carroll Financial Associates held its LogicBio Therapeutics, Inc. Common Stock (LOGC) position steady in Q4 2021 at 428 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1593.

Carroll Financial Associates first reported a position in LOGC in Q1 2021 and has held it in 4 quarters since. The position peaked at $3K in Q1 2021. 57 funds tracked by Wall St. Rank hold LOGC as of Q4 2021.

  • Carroll Financial Associates held 428 shares of LogicBio Therapeutics, Inc. Common Stock worth $1K as of Q4 2021.
  • Carroll Financial Associates left its LogicBio Therapeutics, Inc. Common Stock share count unchanged in Q4 2021.
  • LogicBio Therapeutics, Inc. Common Stock made up ﹤0.01% of Carroll Financial Associates's portfolio in Q4 2021, its #1593 holding.
  • Carroll Financial Associates first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q1 2021 and has held it in 4 quarters since.
  • Carroll Financial Associates's LogicBio Therapeutics, Inc. Common Stock position peaked at $3K in Q1 2021.
  • 57 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.